What Is CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin is a research blend that pairs two growth-hormone secretagogues: CJC-1295, a synthetic analogue of growth-hormone-releasing hormone (GHRH), and Ipamorelin, a selective growth-hormone secretagogue. The two are studied together as reference compounds for research into the growth-hormone / IGF-1 axis. These are investigational compounds and are not approved medicines.
Classification and structure
- CJC-1295 (No DAC) — a modified GHRH (1–29) analogue; “No DAC” denotes the form without the Drug Affinity Complex modification.
- Ipamorelin — a selective pentapeptide growth-hormone secretagogue that acts at the ghrelin / growth-hormone-secretagogue (GHS) receptor.
Mechanism studied in research
Research characterises the two components by their receptor targets:
- CJC-1295 — studied at the GHRH receptor.
- Ipamorelin — studied at the ghrelin / GHS receptor, noted in the literature for its selectivity.
Research on the combination investigates their effect on growth-hormone secretion in study models.
These statements describe the published scientific record; they are not claims about any effect in humans.
Research background
The original pharmacology of each component is documented in the primary literature — Ipamorelin as the first selective growth-hormone secretagogue, and CJC-1295 as a long-acting GHRH analogue — alongside the IUPHAR classification of the growth-hormone-secretagogue (ghrelin) receptor. References are listed below.
Purity, testing and handling
Lazarus Labs supplies this blend as a lyophilised reference material, independently tested to 99%+ purity, with a batch Certificate of Analysis (COA). Store cold and protected from light, per standard laboratory practice.
References
- Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology. 1998. PMID: 9849822.
- Davenport AP, Bonner TI, Foord SM, et al. Pharmacological Reviews. 2005. PMID: 16382107.
- Alba M, Fintini D, Sagazio A, et al. American Journal of Physiology – Endocrinology and Metabolism. 2006. PMID: 16822960.
- Ionescu M, Frohman LA. Journal of Clinical Endocrinology & Metabolism. 2006. PMID: 17018654.
Primary literature, verified against PubMed. Citations are provided for scientific reference and do not imply any human-use indication.
Important
For research use only. Not for human or veterinary consumption. These are investigational compounds and are not approved therapeutic goods. Lazarus Labs supplies them solely as laboratory reference materials and makes no therapeutic, medical or performance claims. Nothing on this page is medical advice or a recommendation to administer these compounds to humans or animals.